Rhythm Pharmaceuticals' setmelanotide sustains 18.8% mean BMI reduction at two years in Phase 3 trial
RYTM•Rhythm Pharmaceuticals said setmelanotide sustained a mean 18.8% BMI reduction at two years in the Phase 3 TRANSCEND trial of acquired hypothalamic obesity.




